Edanz joins M3 Group, strengthens evidence solutions and publication support to 5-million physicians and healthcare professionals around the world

Edanz Group Japan Inc. (“edanz”: Fukuoka, Japan; URLs: https://www.edanzwriting.com & https://www.edanzediting.com), the global leader in high-quality scientific and medical research support, has joined M3, Inc. the global leader in healthcare information services, (TSE 2413: Tokyo, Japan; URL: https://corporate.m3.com/; CEO: Itaru Tanimura; “M3” below). M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare-related information to over 270,000 physician members in Japan, offering marketing and clinical trial services. M3 operates in 10 of the countries with the largest healthcare systems, including the US, UK, France, China, Korea, and India, with over 5 million physicians as members across its global platforms.

As part of the M3 group, Edanz is focused on delivering high-quality scientific and medical manuscript publication support services and specialized research support services. Edanz provides medical writing, gap and situational analyses, strategic publication plans, protocol design, and educational tools and solutions to pharmaceutical and healthcare companies, and individual physicians and biomedical researchers.

Edanz will operate independently within the M3 group, continuing to support all research areas, with its core operations in Japan and China, and a global team of high-quality scientific and editorial experts. The demand for evidence generation has been expanding rapidly, and Edanz expects to scale its support services, and to seek collaboration with global academic publishers and learned societies to develop services to support 5 million M3 platform members, including 2.5 million members in China.

Chief Executive Officer
Koji Yamashita
————————————————————–

Edanz Group Japan株式会社(本社:福岡、代表取締役 山下幸侍、以下「エダンズ」)は、エムスリー株式会社(本社:東京港区 代表取締役、谷村格、以下「エムスリー」)のプレスリリースにもありましたように、4月よりエムスリーグループを通じて、従来の研究全分野に加え、世界500万人の医師や医療従事者、そして製薬企業等へ、医学・科学的エビデンスソリューションと出版サポートを展開します。

エダンズは医師、研究者、そして学術出版編集者などを世界中にネットワーキングし、科学および医学の原稿出版支援および専門的な研究支援において、トップレベルのサービスを提供しています。今後は、国内27万人、中国250万人などを含む、エムスリーグループのプラットフォーム会員である世界500万人の医師に対しても、学術論文の出版サポートに加え、需要が高まっている医薬品業界におけるエビデンスジェネレーション(科学的根拠の生成)や、リアルワールドエビデンスの生成についての支援サービスを強化・展開していきます。

より広く医療・研究をバックアップすべく、邁進してまいります。

代表取締役社長

山下幸侍
————————————————————–
For media inquiries:
Sam Kinred, Marketing Manager, Edanz
skinred “at” edanzgroup.com